Please login to the form below

oral semaglutide

This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk launches late-stage study in Alzheimer’s disease

Study will evaluate oral semaglutide in neurodegenerative disease. Novo Nordisk is planning to enter a late-stage development programme with the launch of a phase 3a study of oral semaglutide in ... Novo Nordisk markets oral semaglutide as Ryblesus in

Latest news

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Since then, the oral diabetes drug has been approved in
Lilly’s Trulicity scores CV reduction indication in the US

The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto
New drugs drive Novo Nordisk despite insulin price pressures

This included a boost from GLP-1 agonist Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in
Givlaari, Rybelsus lead crowded CHMP recommendations

Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide.
Novo Nordisk gets MACE prevention claim for Ozempic in US

At the same time, the FDA also updated the label for Novo Nordisk’s oral formulation of semaglutide – called Rybelsus – to reflect data from the PIONEER 6 study backing its cardiovascular ... For now, it’s the only GLP-1 drug on the market that

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

On our best behaviour

Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
Cortellis Drugs to Watch in 2020 report

Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which entered the market ahead of rimegepant. ... 7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide
Oral biologics delivery still elusive

Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Director – Creative Healthcare Communications: Competative

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

PMHub

Add my company

Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...